Trial Profile
Everolimus for the treatment of lymphangiomatosis, Gorham-Stout disease and vascular anomalies
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 20 Feb 2015
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Lymphangioma; Osteolysis; Vascular disorders
- Focus Therapeutic Use
- 19 Feb 2015 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan.
- 22 Aug 2014 New trial record